Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,723 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.
Cho BC, Chiu CH, Massarelli E, Buchschacher GL, Goto K, Overbeck TR, Loong HHF, Chee CE, Garrido P, Dong X, Fan Y, Lu S, Schwemmers S, Bordogna W, Zeuner H, Osborne S, John T. Cho BC, et al. Among authors: goto k. Lung Cancer. 2024 Feb;188:107442. doi: 10.1016/j.lungcan.2023.107442. Epub 2023 Dec 15. Lung Cancer. 2024. PMID: 38171156 Free article.
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K; LIBRETTO-431 Trial Investigators. Zhou C, et al. Among authors: goto k. N Engl J Med. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870973 Free PMC article. Clinical Trial.
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Drilon A, et al. Among authors: goto k. N Engl J Med. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299. N Engl J Med. 2024. PMID: 38197815 Clinical Trial.
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions.
Kim DW, Schram AM, Hollebecque A, Nishino K, Macarulla T, Rha SY, Duruisseaux M, Liu SV, Al Hallak MN, Umemoto K, Wesseler C, Cleary JM, Springfeld C, Neuzillet C, Joe A, Jauhari S, Ford J, Goto K. Kim DW, et al. Among authors: goto k. Future Oncol. 2024;20(16):1057-1067. doi: 10.2217/fon-2023-0824. Epub 2024 Feb 13. Future Oncol. 2024. PMID: 38348690 Clinical Trial.
Recurrent GRHL fusions in a subset of sebaceoma: microscopic and molecular characterisation of eight cases.
Legrand M, Louveau B, Macagno N, Mancini M, Kazakov DV, Pissaloux D, Tirode F, Tallet A, Mourah S, Lepiller Q, de la Fouchardière A, Sohier P, Frouin E, von Deimling A, Goto K, Cribier B, Calonje E, Taibjee S, Battistella M, Kervarrec T. Legrand M, et al. Among authors: goto k. Histopathology. 2024 Nov 20. doi: 10.1111/his.15361. Online ahead of print. Histopathology. 2024. PMID: 39564735
Glutaminolysis is associated with mitochondrial pathway activation and can be therapeutically targeted in glioblastoma.
Miki K, Yagi M, Hatae R, Otsuji R, Miyazaki T, Goto K, Setoyama D, Fujioka Y, Sangatsuda Y, Kuga D, Higa N, Takajo T, Hajime Y, Akahane T, Tanimoto A, Hanaya R, Kunisaki Y, Uchiumi T, Yoshimoto K. Miki K, et al. Among authors: goto k. Cancer Metab. 2024 Nov 19;12(1):35. doi: 10.1186/s40170-024-00364-0. Cancer Metab. 2024. PMID: 39563470 Free PMC article.
Nurse-Led Screening-Triggered Early Specialized Palliative Care Program for Patients With Advanced Lung Cancer: A Multicenter Randomized Controlled Trial.
Matsumoto Y, Umemura S, Okizaki A, Fujisawa D, Yamaguchi T, Oyamada S, Miyaji T, Mashiko T, Kobayashi N, Satomi E, Kiuchi D, Morita T, Uchitomi Y, Goto K, Ohe Y. Matsumoto Y, et al. Among authors: goto k. Cancer Med. 2024 Nov;13(22):e70325. doi: 10.1002/cam4.70325. Cancer Med. 2024. PMID: 39556485 Free PMC article. Clinical Trial.
NETosis in pulmonary pleomorphic carcinoma.
Oi H, Taki T, Kuroe T, Sakamoto N, Sakashita S, Kojima M, Sugiyama E, Umemura S, Sakai T, Izumi H, Zenke Y, Matsumoto S, Yoh K, Ishii M, Tsuboi M, Goto K, Ishii G. Oi H, et al. Among authors: goto k. Cancer Sci. 2024 Nov 18. doi: 10.1111/cas.16332. Online ahead of print. Cancer Sci. 2024. PMID: 39555736 Free article.
Primary resistance to nivolumab plus ipilimumab therapy affects second-line treatment outcomes in patients with metastatic renal cell carcinoma.
Mori K, Numakura K, Matsushita Y, Kojima T, Osawa T, Sazuka T, Hatakeyama S, Goto K, Yamana K, Kandori S, Kimura T, Nishiyama N, Bando Y, Fujita K, Ueda K, Tanaka H, Tomida R, Kurahashi T, Kitamura H, Miyake H, Habuchi T. Mori K, et al. Among authors: goto k. Cancer Sci. 2024 Nov 17. doi: 10.1111/cas.16326. Online ahead of print. Cancer Sci. 2024. PMID: 39550694 Free article.
3,723 results